BiTE-ing into prostate cancer with bispecific T cell engagers
Abstract
Targeting prostate-specific membrane antigen (PSMA) has important therapeutic ramifications, more recently including immune oncology. Data were recently presented on the preclinical efficacy of a half-life extended bispecific T cell engager, AMG 160, which binds PSMA and CD3 to induce T cell-driven cytolytic activity against prostate cancer.
- Received February 16, 2021.
- Revision received February 25, 2021.
- Accepted March 3, 2021.
- Copyright ©2021, American Association for Cancer Research.
Published at Fri, 12 Mar 2021 18:52:33 +0000